1Marx SO,Jayaraman T,Go LO,et al.Rapamycin-FKBP inhibits cell cycle regulators of prolife ration in vascular smooth muscle cells.Circ Res,1995,76:412
2Poon M,Badimon JJ,Fuster V.Overcoming restenosis with sirolimus:From alphabet soup to clinical reality.Lancet,2002,259:619
3Fattori R and Piva T.Drug-eluting stents in vascular intervention.Lancet,2003,361:247
4Klugherz BD,Llanos G,Lieuallen W,et al.Twenty-eight day efficacy and phamacokinetics of the sirolimus-eluting stents.Coronary Artery Disease,2002,13:183
5Suzuki K,Kopia G,Bailey L,et al.Stent-based delivery of sirolimuse reduces neointimal formation and in-stent restenosis in a porcine coronary model.Circulation,2001,104:1188
6Farb A,Heller PF,Shroff S,et al.Pathological analysis of local delivery of paclitaxel via a polymer-coated stent.Circulation,2001,104:473
7Sollott ST,Cheng L,Pauly RR,et al.Taxol inhibits neointimal smooth muscel cell accumulation after angioplasty in the rat.J Clin Invest,1995,95:1869
8Axel DI,Kunert W,Goggelmann C,et al.Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.Circulation,1997,96:636
9Sousa JE,Costa MA,Abizaid A,et al.Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries:A quantitative coronary angiography and three-dimensional intravascular ultrasound study.Circulation.2001,103:192
10Degertekin M,Serruys PW,Foley DP,et al.Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation:Long-term (up to 2 years) clinical,angiographic,and intravascular ultrasound follow-up.Circulation,2002,106:1610
